Next Article in Journal
Fungal Strategies to Evade the Host Immune Recognition
Previous Article in Journal
Conserved Inhibition of Neutrophil Extracellular Trap Release by Clinical Candida albicans Biofilms
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
J. Fungi 2017, 3(3), 50; doi:10.3390/jof3030050

Verapamil Inhibits Aspergillus Biofilm, but Antagonizes Voriconazole

1
California Institute for Medical Research, 2260 Clove Dr., San Jose, CA 95128, USA
2
Division of Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, CA 94305, USA
Permanent address: Department of Medical Microbiology, Faculty of Medicine, Istanbul University, Istanbul 34452, Turkey.
*
Author to whom correspondence should be addressed.
Received: 10 August 2017 / Revised: 15 September 2017 / Accepted: 18 September 2017 / Published: 20 September 2017
View Full-Text   |   Download PDF [1401 KB, uploaded 20 September 2017]   |  

Abstract

The paucity of effective antifungals against Aspergillus and increasing resistance, the recognition of the importance of Aspergillus biofilm in several clinical settings, and reports of verapamil—a calcium channel blocker—efficacy against Candida biofilm and hyphal growth, and synergy with an azole antifungal in vitro, led to a study of verapamil ± voriconazole against Aspergillus. Broth macrodilution methodology was utilized for MIC (minimum inhibitory concentration) and MFC (minimum fungicidal concentration) determination. The metabolic effects (assessed by XTT [2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt]) on biofilm formation by conidia were studied upon exposure to verapamil, verapamil plus voriconazole, or voriconazole alone. For biofilm formation, we found less inhibition from the combinations than with either drug alone, or less inhibition from the combination than that of the more potent drug alone. For preformed biofilm, we found no significant change in activity comparing voriconazole alone compared to added verapamil, and no significant alteration of activity of the more potent voriconazole, at any concentration in the range tested, by addition of a concentration of verapamil that is inhibitory alone. In full checkerboard assays with planktonic fungus, there was no indication of any effect of one drug on the other (indifference). Although verapamil was similarly inactive against planktonic Aspergillus, as with Candida, verapamil was indeed active against Aspergillus biofilm. However, indifference and antagonism was found with voriconazole. View Full-Text
Keywords: verapamil; Aspergillus; biofilm; voriconazole verapamil; Aspergillus; biofilm; voriconazole
Figures

Figure 1a

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nazik, H.; Choudhary, V.; Stevens, D.A. Verapamil Inhibits Aspergillus Biofilm, but Antagonizes Voriconazole. J. Fungi 2017, 3, 50.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Fungi EISSN 2309-608X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top